A recent study reveals genetically engineered donor islet cells functioning 14 months post-transplant without immunosuppressants, marking a significant step towards a potential cure for type 1 diabetes amidst ongoing technological and ethical debates.
Recent developments in diabetes care are pointing in sharply different directions: some are edging towards a future with fewer burdensome treatments, while others are reminding clinicians and patients how fragile the current ecosystem can be. Among the most striking is Sana Biotechnology’s report that genetically modified donor islet cells continued to function 14 months after transplantation into a man with long-standing type 1 diabetes, without the use of immunosuppressive drugs. According to the company, the cells remained active, produced insulin in response to glucose and appeared to evade immune detection, offering an early glimpse of what a functional cure might look like if the approach can be replicated in larger studies.
That result is notable not only because it avoids the toxicities associated with lifelong immune suppression, but also because it addresses one of the field’s central obstacles: keeping transplanted insulin-producing cells alive long enough to matter. The study is still limited to a single patient, and researchers will need to establish whether the same effect can be reproduced with stem cell-derived tissue, in more people and over longer periods. Even so, the finding adds momentum to a line of research that has long promised much and delivered little beyond short-lived proof of concept.
At the same time, day-to-day diabetes care remains full of friction. Wearable devices such as continuous glucose monitors and insulin pumps have transformed management for many people, but skin reactions continue to undermine their use. Reports highlighted by diabetes advocates and allergy specialists describe redness, itching, burning and rash as common complaints, with repeated culprits including colophony, nickel, ethyl cyanoacrylate, balsam of Peru and phenol-formaldehyde resin. These allergens can appear in adhesives as well as in device components, and the problem is increasingly recognised as a barrier to sustained use rather than a minor inconvenience.
Another technology now moving closer to the market is continuous ketone monitoring, which could prove useful for detecting diabetic ketoacidosis earlier. Diabetes technology experts have been discussing how dual glucose-ketone sensing might help patients and clinicians respond before ketones become dangerously elevated. Abbott is preparing to launch a dual glucose-ketone monitor in the United States, while Dexcom has indicated that its next-generation device is also expected to include similar detection capabilities. Supporters argue that such tools could improve safety; sceptics warn that more data will only help if clinicians can actually act on it.
The business of diabetes care is also broadening beyond hardware and glucose metrics. Insulet has teamed up with the mental health platform Calm to offer free mindfulness tools tailored to people with diabetes, including meditations, breathing exercises and a sleep story narrated by model and diabetes advocate Lila Moss. The collaboration reflects a growing recognition that emotional strain, burnout and sleep disruption are not side issues but part of the condition itself. Insulet has said diabetes distress is widespread, and the company is positioning mental wellbeing as a practical component of management rather than an optional extra.
Kidney disease remains another major front in type 1 diabetes. New data on finerenone suggest the drug may improve kidney outcomes in people with type 1 diabetes and chronic kidney disease, building on prior evidence in type 2 diabetes. In the reported study, urine albumin-to-creatinine ratio fell more sharply in the finerenone group than in the placebo group over six months, indicating a meaningful reduction in kidney stress. The results are encouraging, though broader adoption will depend on confirmation in larger trials and on how the drug performs across different patient groups.
Bigger questions about the direction of diabetes technology are also being debated. Some specialists argue that dual-hormone pumps, which add glucagon to insulin in an effort to mimic the pancreas more closely, may be a solution in search of a problem. Their critics contend that modern insulin-only automated delivery systems, together with adjunct medicines such as GLP-1 and GIP/GLP-1 agents, offer a more practical path forward. Concerns remain about the long-term safety, immunogenicity and day-to-day complexity of chronic glucagon delivery, and the argument is increasingly shifting from whether the concept is elegant to whether it is truly necessary.
Meanwhile, the American Diabetes Association is still dealing with the fallout from its recent conference controversy, in which five scientists were removed from the meeting and had their badges confiscated after distributing an editorial. That episode has prompted sharp criticism from within the diabetes community and renewed debate about the organisation’s leadership, its handling of dissent and its wider role in the research ecosystem. For many in the field, the incident has become a symbol of a larger tension: a science community pushing towards innovation and openness, and institutions still struggling with how best to manage disruption, politics and public accountability.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
